EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma

Author:

Vo Duc1ORCID,Liu Yan1ORCID,Sood Anil K.2,Rezvani Katy3,Jazaeri Amir A.2,Liu Jinsong1ORCID

Affiliation:

1. MD Anderson Cancer Center, Department of Anatomical Pathology, Houston, TX, USA

2. MD Anderson Cancer Center, Department of Gynecologic Oncology & Reproductive Medicine, Houston, TX, USA

3. MD Anderson Cancer Center, Department of Stem Cell Transplantation, Houston, TX, USA

Abstract

High grade epithelial ovarian carcinoma is an aggressive tumor. Treatment includes platinum therapy, however it recurs in most patients due to therapy resistance. In this project, we study the immunohistochemical (IHC) expression of five potential biomarkers/prognostic markers in high grade epithelial ovarian carcinoma: EGFR, HLA-G, CD70, c-MET, and NY-ESO1. A cohort of 274 patients is used. We compare the IHC expression with age, stage, ascites status, family history of cancer, disease free survival (DFS) and overall survival (OS). EGFR expression is significantly correlated with family history and worse OS. HLA-G is associated with worse OS. To confirm the results of EGFR and HLA-G, a second separated cohort of 248 patients is used. Positive EGFR expression again shows worse OS, while HLA-G expression has worse prognostic trend. CD70 has a worse OS trend. C-MET and NY-ESO1 do not have any clinical correlations. EGFR can potentially serve as target in future clinical immune therapy trials.

Publisher

IOS Press

Reference30 articles.

1. Ovarian cancer in the world: Epidemiology and risk factors;Momenimovahed;Int J Womens Health,2019

2. The dualistic model of ovarian carcinogenesis: Revisited, revised, and expanded;Kurman;Am J Pathol,2016

3. Ovarian cancer statistics, 2018;Torre;CA Cancer J Clin,2018

4. Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer;Gockley;Obstet Gynecol,2017

5. New developments in molecular targeted therapy of ovarian cancer;Guan;Discov Med,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3